Non-Alcocholic Fatty Liver Disease: Modern View on Pathogenesis, Diagnosis and Treatment

V.B. Yagmur

Abstract


The article describes the modern views on the causes, mechanisms of development and treatment of nonalcoholic fatty liver disease (NAFLD). The main mechanisms for the accumulation of fat in the liver are an excess intake, synthesis, and their lack of their excretion. Besides numerous adipocytokines, the progression of fatty liver disease with cirrhosis is influenced by oxidative stress. For the diagnosis of NAFLD, modern instrumental and laboratory methods are being used, but the most sensitive method is a morphological study. The main objective in treating NAFLD — prevention of its progression. Treatment strategies are based on therapy of associated metabolic disorders (diabetes, hyperlipidemia) and includes lifestyle modification, use of insulin sensitizers. The article is also discussed new trends in the pathogenetic treatment of hepatic steatosis.


Keywords


non-alcoholic fatty liver disease; metabolic syndrome; adipocytokines; insulin resistance; lipotoxicity

References


Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease / [Brunt M.E., Ramrakhiani M.D., Barry G.C. et al.] // Mod. Pathol. — 2003. — Vol. 16, № 1. — P. 49-56.

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis / [Argo C.K., Northup P.G., Al-Osaimi A.M. et al.] // J. Hepatol. — 2009. — V. 51. — P. 371-379.

Yoshitaka Takuma, Kazuhiro Nouso. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: Our case series and literature review // World J. Gastroenterol. — 2010. — Vol. 16, № 12. — P. 1436-1441.

Adams L.A., Lymp J.F., Sauver J.St. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study // Gastroenterology. — 2005. — V. 129. — P. 113-121.

Loria P., Adinolfi LE , Bellentani S. et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A Decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee / NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato // Dig Liver Dis. — 2010. — Vol. 42, № 4. — P. 272-82.

Amarapurkar D., Kamani P., Patel N. et al. Prevalence of non-alcoholic fatty liver disease: population based study // Ann. Hepatol. — 2007. — V. 6. — P. 161-163.

Angulo P. Epidemiology: nonalcoholic fatty liver disease // Alimentary Pharmacology & Therapeutics. — 2007. — V. 25. — P. 883-889.

Hu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. X. Hu, Y. Huang, Z. Bao et al. // BMC Gastroenterol. — 2012 Sep. — 14, 12. — 123.

Oh M.K., Winn J., Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease // Ailment. Pharmacol. Ther. — 2008. — Vol. 28. — P. 503-522.

Min H.K. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease / H.K. Min, A. Kapoor, M. Fuchs et al. // Cell Metab. — 2012 May. — 2; 15(5). — 665-74.

Almeda-Valdés P., Cuevas-Ramo D., Aguilar-Salinas C.A. Metabolic syndrome and non-alcoholic fatty liver disease // Ann. Hepatol. — 2009. — (Suppl. 1). — S 18-S24.

Musso G., Gambino R., Simona Bo et al. Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects // Diabetes Care March. — 2008. — № 31. — P. 562-568.

Kim S. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease / S. Kim, H. Know, J.H. Park et al. // BMC Gastroenterol. — 2012 Jun. — 12;12. — 69.

Takahashy Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver / Y. Takahashy // Endocr. J. — 2012. — 59(11). — 955-62.

Xu L. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study / L. Xu, C. Xu, C. Yu et al. // PLoS One. — 2012. — 7(8). — e44136.

Estep J.M., Baranova A., Hossain N. et al. Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis // Obes. Surg . — 2009. — Vol. 19. — P. 617-624.

Anty R., Lemoine M. Liver fibrogenesis and metabolic factors // Clin. Res. Hepatol. Gastroenterol. — 2011. — Vol. 35, Suppl. 1. — S10-20.

Ong J.P., Younossi Z.M. Epidemiology and natural history of NAFLD and NASH // Clin. Liver Dis. — 2007. — Vol. 11. — P. 1-16.

Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K. et al. The treatment with antibody of TNF-α reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine — and choline-deficient diet // Inflammation. — 2008. — Vol. 31, № 2. — P91-98.

Harwood H.J. Jr. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis // Neurophatmacology. — 2011. — Dec 17. — Р. 543-556.

Garcia-Ruiz C., Mari M., Colell A. et al. Metabolic therapy: lessons from liver diseases // Curr. Pharm. Des. — 2011. — Vol. 17, № 35. — P3933-44.

Ludwig J., Viggiano T.R., McGill D.B. et al Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin. Proc. — 1980. — Vol. 55. — P. 434-439.

Zhan Y.T., An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease // World J. Gastroenterol. — 2010. — Vol. 16, № 37. — P. 4652-4660.

Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis / World J. Gastroenterol. — 2012 Jun. — 7, 18(21). — 2609-18.

Angulo M.D. Nonalcoholic fatty liver disease // The New England Journal of Medicine. — 2002, April 18. — Vol. 346, № 16.

Baršić N. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease / N. Baršić, I. Lerotic, L. Smircic-Duvnjak et al. // World J. Gastroenterology. — 2012 Aug 14; 18(30): 3945-54.

Hagara D. New aspects in sonography of the liver / D. Hagara, H.R. Schwarzenbach, A. Cerny // Praxis (Bern 1994). — 2012 Sep. — 5; 101(18). — 1161-6.

Hurjui D.M. Non-alcoholic fatty liver disease is associated with cardiovascular risk factors of metabolic syndrome. Hurjui D.M., Nita O., Graur L.I., Micalache L. et al. // Rev. Med. Chir. Soc. Med. Nat. Lasi. — 2012 Jul-Sep. — 116(3). — 692-9.

Adams L.A., Angulo P. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease // Clin. Liver Dis. — 2007. — V. 11. — P. 25-35.

Brunt E.M. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network / E.M.Brunt, D.E. Kleiner, L.A.Wilcon et al. // Hepatology. — 2009 Mar. — 49(3). — 809-20.

Kleiner D.E. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. D.E. Kleiner, E.M. Brunt, M. Van Natta et al. // Hepatology. — 2005 Jun. — 41(6). — 1313-21.

Mahmoud A.A. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD / A.A. Mahmoud, A.S. Bacir, S.S. Shabana // Saudi J. Gastroenterology. — 2012 Sep-Oct. — 18(5). — 327-33.

Valenty L. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease / L. Valenty, P. Dongiovanni, S. Fargion // World J. Gastroenterol. — 2012 Aug 7. — 18(29). — 3782-6.

Yoon M.Y. Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH / M.Y. Yoon, J.M. Sung, C.S. Song et al. // Clin. Mol. Hepatol. — 2012 Sep. — 18(3). — 279-86.

Feldstein A.E. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study / A.E. Feldstein, A. Wieckowska, A.R. Lopez et al. // Hepatology. — 2009 Oct. — 50(4). — 1072-8.

Valenti L. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls / L. Valenty, R. Rametta, M. Ruscica et al. // BMC Gastroenterol. — 2012 Aug 16. — 12. — 111.

Li Y. Genetic variant I148M in PNPLA3 is associated with the ultrasonography-determined steatosis degree in a Chinese population / Y. Li, C. Xing, Z. Tian, H.C. Ku // BMC Med. Genet. — 2012 Nov 23. — 13. — 113.

Chalasani Naga. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association / Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl et al. // Hepatology. — 2012. — Vol. 55. — № 6.

Promrat K. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis / K. Promrat, D.E. Kleiner, H.M. Niemeier, E. Jackvony et al. // Hepatology. — 2010. — 51. — 121-129.

Shojaee-Moradie F. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism / F. Shojaee-Moradie, K.C. Baynes, C. Pentecost, J.D. Bell et al. // Diabetologia. — 2007. — 50. — 404-413.

Liu X., Lazenby A.J., Clements R.H. et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery // Obes. Surg. — 2007. — Vol. 17. — P. 486-492.

Barker K.B., Palekar N.A., Bowers S.P. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery // Am. J. Gastroenterol. — 2006. — V. 101., P. 368-373.

Mattar S.G., L.M.Velcu, M. Rabinovitz. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome // Ann. Surg. — 2005. — Vol. 242. — P. 610-617.

Mummadi R.R. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis / R.R. Mummadi, K.S. Kasturi, S. Chennareddygari, G.K. Sood // Clin. Gastroenterol. Hepatol. — 2008. — № 6. — P. 1396-1402.

Harrison S.A., Fecht W., Brunt E.M., Neuschwander-Tetri B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial // Hepatology. — 2009. — Vol. 49. — P. 80-86.

Lewis J.H., Mortensen M.E., Zweig S. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial // Hepatology. — 2007. — Vol. 46. — P. 1453-1463.

Malhi H., Gores G.J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease // Semin. Liver Dis. — 2008. — Vol. 28. — P. 360-369.

Shargorodsky M. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? / M. Shargorodsky, E. Omelchenko, Z. Matas et al. // Cardiovasc. Diabetol. — 2012 Jun 7. — 11. — 61.

Aithal G.P., Thomas J.A., Kaye P.V. et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis // Gastroenterology. — 2008. — V. 135. — P. 1176-1184.

Tsochatzis E.A., Papatheodoridis G.V., Archimandritis A.J. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy // Mediators Inflamm. — 2009. — Р. 831-840.

Lee J., Hong S.W., Chae S.W. et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice // PloS One. — 2012. — Vol. 7, № 2. — P. 63-72.

Chalasani N.P., Sanyal A.J., Kowdley K.V. et al. NASH CRN Research Group Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design // Contemp. Clin. Trials. — 2009. — V. 30. — P. 88-96.

Cheng J. Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH) // J. Cheng, A. Joyce, K. Yates et al. // PLoS One. — 2012. — 7(9). — e44106.

Cichoz-Lach H., Celinski K., Konturek P.C. et al. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis // J. Physiol. Pharmacol. — 2010. — Vol. 61, № 5. —P. 577-580.

Abdelmalek M.F., Sanderson S.O., Angulo P. et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial // Hepatology. — 2009. — Vol. 50, № 6. — P. 1818-26.

Lindor K.D., Kowdley K.V., Heathcote E.J. et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial // Hepatology. — 2004. — Vol. 39. — P. 770-778.

Purohit V., Abdelmalek M.F., Barve S. et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium // Am. J. Clin. Nutr. — 2007. — Vol. 86. — P. 14-24.

Feher H., Lengvel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer // Curr. Pharm. Biotechnol. — 2012. — Vol. 13, № 1. — P. 210-217.

Zein C.O., Yerian L.M., Goate P. et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial // Hepatology. — 2011. — Vol. 54, № 5. —

P. 1610-1619.

Li W., Zheng L., Sheng C. et al. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease // Lipids. Health Dis. — 2011. — Vol. 8, № 10. — P49-54.

Naveau S., Chollet-Martin S., Dharancy S. et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis // Hepatology. — 2004. — Vol. 39, № 5. — P. 1390-1397.

Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial // The Lancet. — 2008. — Vol. 371, № 9617. — P. 987-997.

Gayyar Al. M.M., Shams M.E., Barakat E.A. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease // Pharm. Biol. — 2012. — Vol. 50, № 3. — P. 297-303.

Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease // World J. Gastroenterol. — 2011. — Vol. 17, № 2. — P. 271-272.

Machado M.V. Gut microbiota and nonalcoholic fatty liver disease / M.V. Machado, H. Cortez-Pinto // Ann. Hepatol. — 2012 Jul-Aug. — 11(4). — 440-9.




DOI: https://doi.org/10.22141/2308-2097.3.49.2013.86346

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru